Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors

US10112950B2 · kind B2 · utility

Assignee

• Incyte Corporation · US

Inventors

• Liangxing Wu · Wilmington, US
• Joel R. Courter · Glen Mills, US
• Chunhong He · Boothwyn, US
• Jingwei Li · Beijing, CN
• Liang Lu · Hockessin, US
• Yaping Sun · Lexington, US
• Xiaozhao Wang · Readington, US
• Wenqing Yao · Kennett Square, US
• Colin Zhang · Ambler, US
• Jincong Zhuo · Boothwyn, US

Key dates

• Filing date: Jun 5, 2017
• Grant date: Oct 30, 2018
• Expiry date: Jun 5, 2037

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D519/00
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

The present invention is directed to imidazo[1,2-a]pyrazine derivatives of Formula I, or a pharmaceutically acceptable salt thereof, which are LSD1 inhibitors useful in the treatment of diseases such as cancer.